Trial Profile
An Open-label, Multi-center Phase 2 Study to Evaluate Everolimus as Monotherapy Treatment for Patients With Metastatic Recurrent and/or Unresectable Renal Cell Carcinoma (EVERMORE)
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 08 Nov 2021
Price :
$35
*
At a glance
- Drugs Everolimus (Primary)
- Indications Renal cell carcinoma
- Focus Therapeutic Use
- Acronyms EVERMORE
- Sponsors Novartis
- 26 Mar 2019 Status changed from recruiting to completed.
- 27 Feb 2017 Planned End Date changed from 1 Jun 2016 to 30 Mar 2017.
- 27 Feb 2017 Planned primary completion date changed from 1 Jun 2016 to 30 Mar 2017.